Premium
Two different anti‐erythroid monoclonal antibodies in immunodiagnosis of human leukemias: A comparative study
Author(s) -
Tupitsyn N. N.,
Mechetner E. B.,
Baryschnikov A. Ju.,
Drozdova T. S.,
Frenkel M. A.,
Ievleva E. S.,
Kiselev A. V.,
Perilov A. A.,
Peterson I. S.,
Probatova N. A.,
Protasova A. K.,
Rozinova E. N.,
Tonevitsky A. G.,
Volkova M. A.
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910440405
Subject(s) - glycophorin , monoclonal antibody , epitope , haematopoiesis , immunophenotyping , bone marrow , antigen , antibody , lymph node , microbiology and biotechnology , monoclonal , leukemia , immunology , biology , medicine , stem cell , genetics
To date, only anti‐glycophorin‐A monoclonal antibodies (MAbs) have been widely used as anti‐erythroid probes in the diagnosis of leukemias. We have examined blood, bone‐marrow and lymph‐node samples from 474 patients, adults and children, with different hemopoietic malignancies, using a panel of MAbs including 2 anti‐erythroid MAbs directed to glycophorin‐A and an antigen of erythroblasts, Ag‐Eb. MAb HAE9 directed against a human epitope of Ag‐Eb has earlier been shown to be highly specific for immature erythroid cells. Of all the patients, 2.7% demonstrated glycophorin‐A expression on blast cells, while anti‐Ag‐Eb MAb HAE9 reacted positively with cells from 6.0% of patients. Samples from 31 of 474 (6.5%) patients expressed one or both erythroid markers. Our results indicate that MAb HAE9 may be useful, in combination with anti‐glycophorin‐A MAbs, as an anti‐erythroid probe for immunophenotyping human leukemias.